BofA Securities on Hims and Hers (HIMS): 'Trump’s FDA nominee currently works for a GLP-1 compounder'
Tweet Send to a Friend
BofA Securities analyst Michael Cherny reiterated an Underperform rating and $18.00 price target on Hims and Hers (NYSE: HIMS)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
